We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+33.87%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$336M
AUM Growth
+$6.15M
Cap. Flow
-$58M
Cap. Flow %
-17.27%
Top 10 Hldgs %
38.74%
Holding
96
New
16
Increased
28
Reduced
16
Closed
29

Top Buys

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$11.9M
2
SNY icon
Sanofi
SNY
+$10.8M
3
MDT icon
Medtronic
MDT
+$10.3M
4
RCKT icon
Rocket Pharmaceuticals
RCKT
+$8.45M
5
CLDX icon
Celldex Therapeutics
CLDX
+$7.27M

Top Sells

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$20.7M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$11.2M
3
SLNO
Soleno Therapeutics
SLNO
+$8.43M
4
KRYS icon
Krystal Biotech
KRYS
+$8.3M
5
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$7.41M

Sector Composition

Rank Sector Weight
1 Healthcare 96.5%
2 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PMVP icon
51
PMV Pharmaceuticals
PMVP
$60.3M
$1.71M 0.51%
+550,000
New +$1.46M
ALT icon
52
Altimmune
ALT
$580M
$1.69M 0.5%
+150,000
New +$626K
NTLA icon
53
Intellia Therapeutics
NTLA
$1.55B
$1.67M 0.5%
54,822
+1,804
+3% +$51.8K
BCRX icon
54
BioCryst Pharmaceuticals
BCRX
$2.35B
$1.49M 0.44%
248,728
-542,943
-69% -$3.15M
KALV
55
DELISTED
KalVista Pharmaceuticals
KALV
$1.37M 0.41%
111,734
-117,200
-51% -$1.07M
MTEM
56
DELISTED
Molecular Templates, Inc.
MTEM
$1.32M 0.39%
354,608
– –
TRVI icon
57
Trevi Therapeutics
TRVI
$2.61B
$1.16M 0.34%
863,883
-63,532
-7% -$96.2K
SDGR icon
58
Schrodinger
SDGR
$1.15B
$1.11M 0.33%
31,117
+806
+3% +$23.4K
VRDN icon
59
Viridian Therapeutics
VRDN
$2.2B
$1.1M 0.33%
50,438
+3,000
+6% +$47.4K
IMVT icon
60
Immunovant
IMVT
$8.11B
$843K 0.25%
+20,000
New +$736K
MRSN
61
CALL
DELISTED
Mersana Therapeutics
MRSN
$700K 0.21%
12,064
-20,000
-62% -$805K
APLS
62
DELISTED
Apellis Pharmaceuticals
APLS
$599K 0.18%
+10,000
New +$507K
KPTI icon
63
Karyopharm Therapeutics
KPTI
$159M
$486K 0.14%
37,464
– –
ALGS icon
64
Aligos Therapeutics
ALGS
$26.7M
$444K 0.13%
26,740
+1,465
+6% +$25.2K
RLMD icon
65
Relmada Therapeutics
RLMD
$562M
$414K 0.12%
100,000
– –
RZLT icon
66
Rezolute
RZLT
$470M
$156K 0.05%
157,085
-276,155
-64% -$253K
RCKTW icon
67
Rocket Pharmaceuticals Warrant
RCKTW
$342K
$51.4K 0.02%
104,828
– –
ACRS icon
68
CALL
Aclaris Therapeutics
ACRS
$743M
– –
-199,000
Closed -$1.36M
ACRS icon
69
PUT
Aclaris Therapeutics
ACRS
$743M
– –
-2,400
Closed -$16.4K
AKRO
70
CALL
DELISTED
Akero Therapeutics
AKRO
– –
-200,000
Closed -$10.1M
AKRO
71
PUT
DELISTED
Akero Therapeutics
AKRO
– –
-106,600
Closed -$5.39M
ALKS icon
72
Alkermes
ALKS
$8.39B
– –
-41,455
Closed -$1.16M
JBIO
73
Jade Biosciences
JBIO
$1.22B
– –
-2,857
Closed -$1.36M
BMRN icon
74
BioMarin Pharmaceuticals
BMRN
$11.7B
– –
-10,000
Closed -$885K
CLNN icon
75
Clene
CLNN
$64.4M
– –
-25,000
Closed -$248K
1 2
3
4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return

Silverarc Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, Silverarc Capital Management held 96 positions worth $336M, up 1.9% from $330M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Silverarc Capital Management withdrew a net $58M in Q4 2023, closing 29 positions and reducing 16 holdings. Its most notable exit was Immunogen Inc, an estimated $20.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 81% a quarter earlier, followed by Consumer Staples.

Against the trend, Silverarc Capital Management opened a new position in Nuvalent worth $14.2M.

  • Silverarc Capital Management's largest Q4 2023 buy was Nuvalent: 193,000 shares worth $14.2M.
  • Silverarc Capital Management added most to Akero Therapeutics in Q4 2023, an estimated $4.3M increase.
  • Silverarc Capital Management's biggest Q4 2023 reduction was Soleno Therapeutics, cutting an estimated $8.43M.
  • Silverarc Capital Management fully exited Immunogen Inc in Q4 2023, selling an estimated $20.7M.
  • Silverarc Capital Management's ten largest holdings make up 39% of its $336M portfolio in Q4 2023.
  • Silverarc Capital Management opened 16 new positions and closed 29 in Q4 2023.
  • Silverarc Capital Management's portfolio value rose 1.9% quarter-over-quarter to $336M.

Based on Silverarc Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.